The most prescribed treatment for multiple myeloma in 1st line and beyond3*
Category 1 National Comprehensive Cancer Network® (NCCN®) recommended for first line and beyond4‡
More than 1 million patients treated globally since 20031,3†
1 convenient subcutaneous option§ for patients vs IV4-6
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
*Based on data collected from October 2018 through September 2020.
†As of April 2020.3
‡Specifically designated for VRd only.
§Also available for intravenous (IV) use.
VRd=VELCADE, REVLIMID (lenalidomide), dexamethasone.